跳转至内容
Merck
  • Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.

Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.

Pharmacotherapy (1986-07-01)
J A Barone, J J Raia, D B Levy
摘要

Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.

材料
货号
品牌
产品描述

USP
双氢麦角胺 甲磺酸盐, United States Pharmacopeia (USP) Reference Standard
双氢麦角胺 甲磺酸盐, European Pharmacopoeia (EP) Reference Standard
双氢麦角胺 甲磺酸盐, European Pharmacopoeia (EP) Reference Standard